The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
On the back of Chelsea’s Birthday yesterday Covidity is one year old today.
With the increase in the share price from 5p to its current value 23p, funding from Inovate uk, continued support from Vulpes, new investment from Redmile, manufacturing deal with Cobra, selection of SN candidate, increased media coverage both in the National press and two excellent reports from Thomas Moore on Sky news, it has been an excellent year for Scancell.
Although There have been no major RNS’s from Scancell in 2021 so far, the share price has held up pretty well and hopefully in the coming weeks we will have life changing RNS’s for shareholders and more importantly, news that could help save the lives for millions around the world.
Sorry if posted before.
Scancell is presenting at Bioequity Europe between May 17th to May 19th.
https://conferences.biocentury.com/bioequity-europe/presenting-companies
This evening CEPI have tweeted
'The swift development of safe and effective vaccines against covid-19 has been a monumental achievement but we remain in a race against the virus.
Could we provide a broad protection across the field through an all-in-one Corona virus shot?'
They also reposted their link to their March 1st article.
'Going universal The search for an all-in-one Corona virus vaccine.'
'For example, scientists at the University of Nottingham in the UK are working alongside pharmaceutical company Scancell and Nottingham Trent University to test its COVID-19 vaccine candidate, SN14, which targets both the spike protein as well as the nucleocapsid, or N-protein. By targeting this additional viral structure, which is far less likely to mutate, the vaccine if found safe and effective could work to protect people against COVID-19 irrespective of any mutations to the spike protein and, in theory, could work across other coronaviruses.'
https://cepi.net/news_cepi/going-universal-the-search-for-an-all-in-one-coronavirus-vaccine/
A nice mention of investing in Scancell at 8.40 minutes.
In today's edition of 'Sunday Roast' Zak talks to experienced and seasoned investors, Phil Carroll, Albert Arthur and Kevin Hornsby.
https://www.share-talk.com/zaks-sunday-roast-11th-april-analysis-of-stocks-markets-by-traders-and-investors/#gs.xy366u
10 Cheap Healthcare Stocks to Ponder Over This Easter
April 05, 2021 12:37 AM BST
AIM-listed healthcare firm Scancell Holdings develops cancer treatments. Recently, the company has forayed into the research of Covid-19 vaccine. The developer of cancer immunotherapies ended the first quarter of 2021 with £25.7million in cash compared to £3.6 million in April 2020, according to the results for the six-month period ended 31 October 2020. SCLP shares delivered a price return of over 62% since January so far.
https://kalkinemedia.com/uk/stocks/healthcare/10-cheap-healthcare-stocks-to-ponder-over-this-easter
MENAFN 27/3/21
‘On the other hand, Scancell's DNA vaccine forces cancerous cell to express two antigens – gp100 and TRP-2 stimulating a strong T cell response.’
https://menafn.com/1101818330/Cancer-Vaccines-Market-Growth-And-Opportunity
One year on: West Midlands businesses and projects which tell the story of a year in lockdown.
COBRA BIOLOGICS
Biologics firm Cobra Biologics was awarded three million euros in funding in March to support emergency R&D into Covid-19.
The company – which employs 114 people at Keele, Staffordshire, and a further 100 in Sweden – later signed a supply agreement with AstraZeneca to manufacture the AZD1222 vaccine.
The production agreement formed part of AstraZeneca’s in-licensed programme with the University of Oxford to manufacture one of the world’s first coronavirus vaccines.
The company has since entered a good manufacturing practice (GMP) agreement with Scancell for the production of a new vaccine which has the potential to provide long-lasting immunity against Covid-19 and new strains that may arise in the future.
https://www.business-live.co.uk/enterprise/one-year-on-18-west-20203002
On 21st March 2019
Professor Lindy Durrant received the Waldenström award from the Swedish Society of Oncology
https://www.londonstockexchange.com/news-article/SCLP/professor-lindy-durrant-receives-waldenstrom-award/14010019
Scancell is featured in the Greek national newspaper, tovima.gr
(The tribune)
Tovima is a high quality newspaper in Greece. It is historically the newspaper to which Greek politicians use to give interviews and write articles.
'Researchers at the University of Nottingham are working with the pharmaceutical company Scancell and colleagues at the University of Nottingham Trent on a vaccine against SARS-CoV-2, which targets protein N in combination with the protein S of the virus. With this tactic, scientists hope to "bypass" the reef of the new coronavirus mutations and beyond, as they believe that this strategy may prove valuable in developing a
vaccine against a wide range of coronaviruses. They are now preparing a phase I clinical trial of their vaccine codenamed SN14 and believe that, if all goes well, such a promising vaccine could be developed within a year.'
https://www.tovima.gr/2021/03/20/science/kath-odon-pros-ena-katholiko-emvolio-gia-tous-koronoious-fovoi-gia-nees-pandimies/
Titled,
Seven UK Covid vaccine efforts you may not have heard of.
University of Nottingham and Nottingham Trent University.
Scientists at the University of Nottingham and Nottingham Trent University are contributing to a novel DNA-based vaccine candidate, SN14, developed by Oxfordshire-based Scancell Holdings plc.
The project builds on Scancell’s success in producing a cancer vaccine using the same DNA platform, which Nottingham University describes as “safe, cost-effective and suitable for rapid and large-scale manufacture”.
Virologists at Nottingham have identified parts of the coronavirus to target, while scientists at Nottingham Trent helped screen the vaccine for its capacity to trigger immune responses against Covid-19.
The vaccine candidate targets two virus proteins, nucleocapsid and spike, which the team believes will trigger both T-cell and antibody responses, making for better immunity.
“Vaccines are the long-term solution and we believe our combined high avidity T-cell and neutralising antibody approach has the potential to produce a second-generation vaccine that will generate an effective and durable immune response to Covid-19,” said Lindy Durrant, chief scientist at Scancell and professor at University of Nottingham.
https://www.researchprofessionalnews.com/rr-news-uk-innovation-2021-3-seven-uk-covid-vaccine-efforts-you-may-not-have-heard-of/
Vaccine makers fight on to stay ahead of covid-19
https://www.pressreader.com/uk/daily-mirror/20210312/282449941774908
Experts from Nottingham's two universities have teamed up to adapt a cancer treatment for use in the fight against Covid-19.
They are collaborating with Scancell Holdings, a developer of novel immunotherapies for cancer, to move the project forward.
Virologists at the University of Nottingham’s Centre for Research on Global Virus Infections have identified parts of the novel coronavirus they hope will generate an immune response that will prevent future infection.
This information is being used by Scancell to design DNA-based vaccines to allow easy and effective delivery of the virus vaccine into humans to produce virus-killing antibodies and cells.
The project builds on Scancell’s success with its lead ImmunoBody cancer vaccine to treat patients suffering from malignant melanoma.
Although other vaccines may have reached the clinic earlier, the team believe that the combined T cell and antibody approach will give more potent and long-lasting responses, ultimately leading to better protection.
SARS-CoV-2 is the virus that causes COVID-19, and the novel DNA vaccine will target two virus proteins which then enables the virus to gain entry into a cell.
The surface protein is the natural target for virus-killing antibodies, which prevent the virus from entering the cell.
Dr Gillies O'Bryan-Tear, Chief Medical Officer of Scancell, said: "We have already tested it on animals, and we are moving into human trials as soon as possible this year.
"This is a great example of an industry academic collaboration and great UK science."
Graham Pockley, Professor of Immunobiology at Nottingham Trent University’s John van Geest Cancer Research Centre, said: “Nottingham Trent University and the John van Geest Cancer Research Centre are delighted to support Scancell’s endeavours to develop an effective vaccine for COVID-19.
"This exciting research programme highlights the capabilities and skills that are available in Nottingham and the value of collaborative working, not only between universities, but also with commercial partners.”
https://www.nottinghampost.com/news/nottingham-news/coronavirus-vaccine-developed-nottingham-tested-5036839
Professor Jonathan Van-Tam is answering questions at 9.00am tomorrow morning on Sky News. I have already registered my question to him,
'What is your opinion of your old University, Nottingham, creating a Universal Vaccine that can be effective against all variants of Covid 19?'
It would be great if a few more similar questions were asked. They are also accepting video questions for the good looking amongst you, lol.
https://news.sky.com/story/covid-19-ask-deputy-chief-medical-officer-jonathan-van-tam-your-coronavirus-questions-12226791
Today there has been no UK press coverage, however, the Scancell part of The Observer article and the Jonathan Ball quotes have been in today's Iran Daily, after the section on climate change.
https://www.pressreader.com/search?query=scancell&languages=en&orderBy=Date&groupBy=Language&hideSimilar=0&type=1&state=1
Most of the article is behind a paywall, but this is the relevant part re Scancell.
The Hunt goes on for second generation vaccines.
'One possible solution is a vaccine – now under development by a team of scientists including Ball – that targets not just the spike protein on the surface of the Covid virus but also another part of the virus, called the N protein.
“Hopefully this should result in much wider response from immune systems and so provide a much
broader immunity to the virus,” Ball told the Observer. “And given what we know now about the emergence of Covid virus variants, that could help us strengthen protection against the disease,” he added.
The project, which also involves the immunology company Scancell and researchers at Nottingham Trent University, has reached a stage where manufacture of the new vaccine has begun.
Ball said it was hoped clinical trials of the vaccine – which is capable of generating antibodies against virus spike proteins as well as core proteins – could be launched very soon.
“The plasmid that forms the basis of the vaccine has already been used in other medical treatments and is tolerated well in patients,” he added. “So we are hopeful that we can press ahead with clinical trials relatively soon.”
https://www.pressreader.com/search?query=scancell&languages=en&groupBy=Language&hideSimilar=0&type=1&state=1
The article link below is in today's Daily Mail, Irish Mail and Scottish Mail.
Covid vaccine in a pill sent in the post.
'Even more important is the development of vaccines that can cope with a virus that can readily mutate. A team from the University of Nottingham is developing just that. Unlike our existing vaccines, which target only the spikes on the virus surface, the Nottingham one also targets the virus nucleocapsid, the shell that contains the virus's genetic material. This shell is much harder for the the virus to change.
By targeting this shell, as well as the virus spikes, the hope is to produce a universal vaccine that works against new, more resistant, variants.
https://www.pressreader.com/ireland/irish-daily-mail/20210220/282394107161628
Zak Mir highlights Scancell on today's Sharetalk.
https://www.share-talk.com/share-talk-bulletin-board-heroes-wednesday-17th-february-2021/#gs.trn2we
Scancell mentioned on Arirang TV.
Next phase of pandemic: Vaccination race against variants.
https://www.google.com/url?sa=t&source=web&rct=j&url=https://m.youtube.com/watch%3Fv%3DSZfMvZvOQ3A&ved=2ahUKEwiu3aOpmfDuAhVKShUIHSOrAGw4FBC3AjAEegQIBhAB&usg=AOvVaw26f9jhDClfQGTnXZ37GMvo
Arirang TV is an English language South Korean television network based in Seoul. It is operated and owned by the Korean international broadcasting foundation.
A universal Covid vaccine may be our best means of escape.
https://www.ft.com/content/c6d663e1-9753-4a92-8d7c-599fd0dd45c7
The Cobra team is very proud to be working with Scancell Pharma on this groundbreaking Covid19 vaccine project.
https://mobile.twitter.com/CobraBiologics/status/1360896582087045121
Botski,
I think we are in print in three Sunday papers, The independent, The Sunday Telegraph and The Sunday Star Times.
https://www.pressreader.com/uk/the-sunday-telegraph/20210214/281848646303659
https://www.pressreader.com/uk/the-independent-1029/20210214/281616718069958
https://www.pressreader.com/search?query=Lindy%20durrant&languages=en&orderBy=Date&groupBy=Language&hideSimilar=0&type=1&state=1
Universal vaccine also being developed in UK in world first.
https://www.pressreader.com/uk/the-independent-1029/20210214/281616718069958